Concerns Over Sale of Nicotine Pouches Targeting Canadian Youth

Regulations by 2FIRSTS.ai
Dec.20.2023
Concerns Over Sale of Nicotine Pouches Targeting Canadian Youth
Canadian health unit warns of 'Zonnic' nicotine pouches sold in Canada, with flavors and packaging appealing to teenagers.

The Windsor-Essex County Health Unit in Canada recently issued a press release highlighting concerns about the sale of nicotine pouches branded as 'Zonnic', which are found to be highly appealing to teenagers due to their flavors and packaging.

 

These nicotine pouches are now widely available for sale in convenience stores and gas stations around the world, alongside other products like snacks and candy. Despite the recommendation from the Canadian Department of Health that individuals under 18 should not use nicotine products, the Windsor-Essex County Health Unit states that these packaged products can be purchased without age verification.

 

The health organization advises parents to have in-depth and open discussions with their children regarding the dangers of nicotine use.

 

These products, due to their addictive nicotine content, serve as a stepping stone to more dangerous substances. This is a trend we are currently experiencing, with the likelihood of teenagers using e-cigarettes to smoke tobacco cigarettes being three times higher than those who do not use them," said Dr. Mehdi Aloosh, a medical officer. "I am deeply concerned that these products could lead to early nicotine addiction in our children.

 

The health authorities of Windsor-Essex County have informed local schools about these products and will closely collaborate with them to adjust school policies to prevent their use on school premises. Considering that these products have recently emerged in Canada, they are currently not covered by anti-smoking and e-cigarette regulations.

 

The health agency stated that currently these packaged products are being sold under the name of natural health products by the Canadian Department of Health, and are being advertised as smoking cessation tools.

 

Health officials will also recommend restricting the access of individuals under the age of eighteen to these products.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Employee Sues KT&G for $2 Billion in Heated Tobacco Patent Dispute
Former Employee Sues KT&G for $2 Billion in Heated Tobacco Patent Dispute
A former KT&G researcher is suing the company for $2 billion, alleging inadequate compensation for a heated tobacco patent. The initial claim is around $72 million, and the case is expected to go to trial.
May.21 by 2FIRSTS.ai
Lower Saxony State in Germany Expands Smoking Ban to E-Cigarettes
Lower Saxony State in Germany Expands Smoking Ban to E-Cigarettes
The state parliament of Lower Saxony, Germany, has passed a new law extending existing public smoking bans to include e-cigarettes and cannabis vaporizers. The legislation was introduced by the Social Democrats and Greens, with support from the Christian Democrats.
May.21 by 2FIRSTS.ai
WHO urges Germany to raise tobacco tax to curb consumption
WHO urges Germany to raise tobacco tax to curb consumption
WHO calls on Germany to significantly increase tobacco tax to limit consumption, while EU plans reform on tobacco tax.
Jun.26 by 2FIRSTS.ai
PMI Brazil CEO Urges Policy Rethink, Backs Smoke-Free Alternatives Like IQOS and Zyn
PMI Brazil CEO Urges Policy Rethink, Backs Smoke-Free Alternatives Like IQOS and Zyn
Branko Svarcic, CEO of Philip Morris Brazil, says the country should rethink its public health approach, especially on e-cigarettes and heated tobacco. While Brazil has banned e-cigarettes since 2009, products like IQOS and Zyn are seen as harm-reduction tools in many countries. He urged the government to learn from global examples and update its policies.
May.26 by 2FIRSTS.ai
GFN Experts Warn: Misinformation is Killing Smokers
GFN Experts Warn: Misinformation is Killing Smokers
At the 2025 Global Forum on Nicotine in Warsaw, experts warned that misinformation about nicotine and safer alternatives is misleading the public and healthcare professionals, hindering smokers’ access to life-saving products.
Jun.27
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
The FDA has launched the Commissioner’s National Priority Voucher (CNPV) program, reducing the review time for certain drugs to as little as 1–2 months. While the program currently applies only to pharmaceuticals, it demonstrates the FDA’s capacity to reform its review pathways. Whether a similar mechanism could extend to tobacco products now appears to be a matter of timing and technical details.
Jun.18